secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0000950170-23-024544
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax enters new $200M at-the-market equity facility with TD Cowen, replacing prior $75M program
--------------------------------------------------------------------------------

- Prior $75M ATM facility terminated on March 26, 2023; gross proceeds of $25M raised before termination.
- New $200M ATM agreement signed May 26, 2023; shares sold at market prices through TD Cowen as agent.
- Compensation to TD Cowen up to 3.0% of gross sales price; indemnification provisions included.
- Offering may be suspended by either party; termination upon full sale or agreement end.
- Cooley LLP legal opinion on Placement Shares filed as Exhibit 5.1 to the 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023024544/0000950170-23-024544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023024544/sndx-20230526.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-024544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer